↓ Skip to main content

Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma

Overview of attention for article published in Medical Oncology, September 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

4 tweeters


2 Dimensions

Readers on

10 Mendeley
Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma
Published in
Medical Oncology, September 2018
DOI 10.1007/s12032-018-1192-6
Pubmed ID

Winston Chew, Charlotte Benson, Khin Thway, Andrew Hayes, Aisha Miah, Shane Zaidi, Alex T. J. Lee, Christina Messiou, Cyril Fisher, Winette T. van der Graaf, Robin L. Jones


Sclerosing epithelioid fibrosarcoma (SEF) is a very rare soft tissue sarcoma subtype. Clinically it is an aggressive tumour; however, to our knowledge there are no published reports regarding the efficacy of chemotherapy in SEF. Therefore, the aim of this study was to document the outcome of a series of patients with SEF treated at a single referral centre with reference to systemic therapy. A retrospective search of a prospectively maintained database was performed to identify all patients diagnosed with SEF between 1990 and 2017. The diagnosis was confirmed in each case by a dedicated soft tissue sarcoma pathologist. We analysed those with recurrent disease and the effect of systemic chemotherapy in the metastatic setting. Thirteen patients were identified, median overall survival from diagnosis and metastasis were 47.3 (95% CI 25.0-131.9) and 16.3 (95% CI 5.3-20.6) months, respectively. In total, 12 (92.3%) patients developed metastatic disease of which 10 died of disease, 1 was lost to follow-up and 1 had recently commenced palliative treatment. Among the 10 patients with metastatic disease, 7 received palliative chemotherapy. Palliative chemotherapy resulted in partial response in 1 patient, stable disease in 3 patients and progressive disease in 3 patients. Median time to disease progression was 2.7 (95% CI 1.2-4.4) months. Two of 13 patients were treated with adjuvant chemotherapy, receiving 6 cycles of liposomal doxorubicin and 1 cycle of doxorubicin, respectively, with a metastasis-free survival of 28.2 and 7.1 months, respectively. SEF is an aggressive sarcoma subtype with a poor outcome and with limited responsiveness to conventional chemotherapy. Patients with this subtype should be considered for participation in clinical trials with novel agents. Further investigation into the biology of this rare disease is required to improve outcomes.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 30%
Other 2 20%
Student > Doctoral Student 1 10%
Student > Ph. D. Student 1 10%
Researcher 1 10%
Other 0 0%
Unknown 2 20%
Readers by discipline Count As %
Medicine and Dentistry 4 40%
Sports and Recreations 1 10%
Nursing and Health Professions 1 10%
Unknown 4 40%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 September 2018.
All research outputs
of 13,483,547 outputs
Outputs from Medical Oncology
of 773 outputs
Outputs of similar age
of 265,097 outputs
Outputs of similar age from Medical Oncology
of 14 outputs
Altmetric has tracked 13,483,547 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 773 research outputs from this source. They receive a mean Attention Score of 2.8. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,097 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.